Seres is serious about balancing bacteria populations in the human body. Seres Therapeutics specializes in microbiome therapeutics, which help restore health to persons whose have an unhealthy (or dysbiotic) microbiome ecology of microorganisms. It is developing biologic drugs to treat metabolic, inflammatory, and infectious diseases, primarily in the colon; its lead drug candidates are SER-109 for the treatment of large-intestine inflammation and SER-262, to prevent recurrence of inflammation. In 2019 the company realigned its pipeline to focus on its highest-priority clinical-stage candidates.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
EMPLOYEES (All Sites)
- ASSETS (MIL USD) 132
REVENUE (MIL USD)
- TICKER SYMBOL MCRB
- Incorporated 2010
- FISCAL YEAR END DEC
- SALES GROWTH % 22.07%
Get in Touch with 176 Contacts and 6 Principals*
Eric D ShaffPresident and Chief Executive Officer
STEPHEN BERENSONChairman of the Board
JOHN G AUNINSExecutive Vice President and Chief Technology Officer
DAVID N COOKExecutive Vice President and Officer